JP2006525293A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2006525293A5 JP2006525293A5 JP2006505833A JP2006505833A JP2006525293A5 JP 2006525293 A5 JP2006525293 A5 JP 2006525293A5 JP 2006505833 A JP2006505833 A JP 2006505833A JP 2006505833 A JP2006505833 A JP 2006505833A JP 2006525293 A5 JP2006525293 A5 JP 2006525293A5
- Authority
- JP
- Japan
- Prior art keywords
- group
- alkyl
- groups
- hydrogen atom
- pyridyl
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- -1 imidazopyrimidinyl Chemical group 0.000 claims description 10
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims description 5
- 125000004076 pyridyl group Chemical group 0.000 claims description 5
- 125000004169 (C1-C6) alkyl group Chemical group 0.000 claims description 4
- 150000001875 compounds Chemical class 0.000 claims description 4
- 125000003785 benzimidazolyl group Chemical group N1=C(NC2=C1C=CC=C2)* 0.000 claims description 3
- 125000001164 benzothiazolyl group Chemical group S1C(=NC2=C1C=CC=C2)* 0.000 claims description 3
- 125000004541 benzoxazolyl group Chemical group O1C(=NC2=C1C=CC=C2)* 0.000 claims description 3
- 125000004093 cyano group Chemical group *C#N 0.000 claims description 3
- 125000002883 imidazolyl group Chemical group 0.000 claims description 3
- 125000005956 isoquinolyl group Chemical group 0.000 claims description 3
- 125000004593 naphthyridinyl group Chemical group N1=C(C=CC2=CC=CN=C12)* 0.000 claims description 3
- 125000004592 phthalazinyl group Chemical group C1(=NN=CC2=CC=CC=C12)* 0.000 claims description 3
- 125000003373 pyrazinyl group Chemical group 0.000 claims description 3
- 125000002098 pyridazinyl group Chemical group 0.000 claims description 3
- 125000000714 pyrimidinyl group Chemical group 0.000 claims description 3
- 125000005493 quinolyl group Chemical group 0.000 claims description 3
- 125000000335 thiazolyl group Chemical group 0.000 claims description 3
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims description 2
- 229910052731 fluorine Inorganic materials 0.000 claims description 2
- 125000001153 fluoro group Chemical group F* 0.000 claims description 2
- 239000001257 hydrogen Substances 0.000 claims description 2
- 229910052739 hydrogen Inorganic materials 0.000 claims description 2
- 125000002887 hydroxy group Chemical group [H]O* 0.000 claims description 2
- 125000004435 hydrogen atom Chemical group [H]* 0.000 claims 5
- 125000006272 (C3-C7) cycloalkyl group Chemical group 0.000 claims 3
- 125000002733 (C1-C6) fluoroalkyl group Chemical group 0.000 claims 2
- 239000002253 acid Substances 0.000 claims 2
- 125000005843 halogen group Chemical group 0.000 claims 2
- LOTBYPQQWICYBB-UHFFFAOYSA-N methyl n-hexyl-n-[2-(hexylamino)ethyl]carbamate Chemical compound CCCCCCNCCN(C(=O)OC)CCCCCC LOTBYPQQWICYBB-UHFFFAOYSA-N 0.000 claims 2
- 125000000719 pyrrolidinyl group Chemical group 0.000 claims 2
- 125000002294 quinazolinyl group Chemical group N1=C(N=CC2=CC=CC=C12)* 0.000 claims 2
- 125000001567 quinoxalinyl group Chemical group N1=C(C=NC2=CC=CC=C12)* 0.000 claims 2
- 150000003839 salts Chemical class 0.000 claims 2
- 239000012453 solvate Substances 0.000 claims 2
- VGGSQFUCUMXWEO-UHFFFAOYSA-N Ethene Chemical group C=C VGGSQFUCUMXWEO-UHFFFAOYSA-N 0.000 claims 1
- 239000005977 Ethylene Substances 0.000 claims 1
- 229910052757 nitrogen Inorganic materials 0.000 description 2
- 125000004433 nitrogen atom Chemical group N* 0.000 description 2
- 125000004191 (C1-C6) alkoxy group Chemical group 0.000 description 1
- 102000009132 CB1 Cannabinoid Receptor Human genes 0.000 description 1
- 108010073366 CB1 Cannabinoid Receptor Proteins 0.000 description 1
- 229940123158 Cannabinoid CB1 receptor antagonist Drugs 0.000 description 1
- 102000018208 Cannabinoid Receptor Human genes 0.000 description 1
- 108050007331 Cannabinoid receptor Proteins 0.000 description 1
- 229940122820 Cannabinoid receptor antagonist Drugs 0.000 description 1
- 239000002220 antihypertensive agent Substances 0.000 description 1
- 229940030600 antihypertensive agent Drugs 0.000 description 1
- 150000001539 azetidines Chemical class 0.000 description 1
- 125000004604 benzisothiazolyl group Chemical group S1N=C(C2=C1C=CC=C2)* 0.000 description 1
- 125000004603 benzisoxazolyl group Chemical group O1N=C(C2=C1C=CC=C2)* 0.000 description 1
- 125000000499 benzofuranyl group Chemical group O1C(=CC2=C1C=CC=C2)* 0.000 description 1
- 125000004196 benzothienyl group Chemical group S1C(=CC2=C1C=CC=C2)* 0.000 description 1
- 239000003555 cannabinoid 1 receptor antagonist Substances 0.000 description 1
- 239000003536 cannabinoid receptor antagonist Substances 0.000 description 1
- 125000005390 cinnolyl group Chemical group N1=NC(=CC2=CC=CC=C12)* 0.000 description 1
- 125000005945 imidazopyridyl group Chemical group 0.000 description 1
- 125000003453 indazolyl group Chemical group N1N=C(C2=C1C=CC=C2)* 0.000 description 1
- 125000001786 isothiazolyl group Chemical group 0.000 description 1
- 125000000842 isoxazolyl group Chemical group 0.000 description 1
- LRNUFCLZJXZYLW-UHFFFAOYSA-N n-piperidin-1-yl-1h-pyrazole-5-carboxamide Chemical class C1=CNN=C1C(=O)NN1CCCCC1 LRNUFCLZJXZYLW-UHFFFAOYSA-N 0.000 description 1
- 125000001624 naphthyl group Chemical group 0.000 description 1
- 125000001715 oxadiazolyl group Chemical group 0.000 description 1
- 125000002971 oxazolyl group Chemical group 0.000 description 1
- 239000008194 pharmaceutical composition Substances 0.000 description 1
- 150000003053 piperidines Chemical class 0.000 description 1
- 125000006085 pyrrolopyridyl group Chemical group 0.000 description 1
- 125000001113 thiadiazolyl group Chemical group 0.000 description 1
- 125000004306 triazinyl group Chemical group 0.000 description 1
- 125000001425 triazolyl group Chemical group 0.000 description 1
- 125000002023 trifluoromethyl group Chemical group FC(F)(F)* 0.000 description 1
- 229940124549 vasodilator Drugs 0.000 description 1
- 239000003071 vasodilator agent Substances 0.000 description 1
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| FR0305540A FR2854633B1 (fr) | 2003-05-07 | 2003-05-07 | Derives de piperidinyl-et piperazinyl-alkylcarbamates, leur preparation et leur application en therapeutique |
| PCT/FR2004/001102 WO2004099176A1 (fr) | 2003-05-07 | 2004-05-06 | Derives de piperidinyl- et piperazinyl-alkylcarbamates, leurs procedes de preparation et leur application en therapeutique |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2010264051A Division JP2011063620A (ja) | 2003-05-07 | 2010-11-26 | ピペリジンおよびピペラジン誘導体 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2006525293A JP2006525293A (ja) | 2006-11-09 |
| JP2006525293A5 true JP2006525293A5 (enExample) | 2007-06-21 |
| JP4669836B2 JP4669836B2 (ja) | 2011-04-13 |
Family
ID=33306203
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2006505833A Expired - Fee Related JP4669836B2 (ja) | 2003-05-07 | 2004-05-06 | ピペリジニル−およびピペラジニル−アルキルカルバメート誘導体、その製造法および治療用途 |
| JP2010264051A Withdrawn JP2011063620A (ja) | 2003-05-07 | 2010-11-26 | ピペリジンおよびピペラジン誘導体 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2010264051A Withdrawn JP2011063620A (ja) | 2003-05-07 | 2010-11-26 | ピペリジンおよびピペラジン誘導体 |
Country Status (26)
| Country | Link |
|---|---|
| US (3) | US7214798B2 (enExample) |
| EP (1) | EP1633735B1 (enExample) |
| JP (2) | JP4669836B2 (enExample) |
| KR (1) | KR20060009900A (enExample) |
| CN (2) | CN1812980B (enExample) |
| AR (1) | AR044178A1 (enExample) |
| AT (1) | ATE535518T1 (enExample) |
| AU (1) | AU2004236006B2 (enExample) |
| BR (1) | BRPI0410123A (enExample) |
| CA (1) | CA2521700A1 (enExample) |
| CO (1) | CO5640105A2 (enExample) |
| EA (1) | EA009468B1 (enExample) |
| FR (1) | FR2854633B1 (enExample) |
| IL (1) | IL171694A (enExample) |
| IS (1) | IS8070A (enExample) |
| MA (1) | MA27791A1 (enExample) |
| ME (1) | MEP22308A (enExample) |
| MX (1) | MXPA05011941A (enExample) |
| NO (1) | NO20055204L (enExample) |
| NZ (1) | NZ542941A (enExample) |
| RS (1) | RS20050805A (enExample) |
| TN (1) | TNSN05253A1 (enExample) |
| TW (1) | TWI337607B (enExample) |
| UA (1) | UA81808C2 (enExample) |
| WO (1) | WO2004099176A1 (enExample) |
| ZA (1) | ZA200508158B (enExample) |
Families Citing this family (32)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB2397067B (en) * | 2002-12-23 | 2005-05-11 | Destiny Pharma Ltd | Porphin & azaporphin derivatives with at least one cationic-nitrogen-containing meso-substituent for use in photodynamic therapy & in vitro sterilisation |
| FR2864080B1 (fr) * | 2003-12-23 | 2006-02-03 | Sanofi Synthelabo | Derives de 1-piperazine-et-1-homopiperazine-carboxylates, leur preparation et leur application en therapeutique |
| FR2866884B1 (fr) * | 2004-02-26 | 2007-08-31 | Sanofi Synthelabo | Derives d'aryl-et d'heteroaryl-piperidinecarboxylates, leur preparation et leur application en therapeutique |
| FR2866888B1 (fr) | 2004-02-26 | 2006-05-05 | Sanofi Synthelabo | Derives de alkylpiperazine- et alkylhomopiperazine- carboxylates, leur preparation et leur application en therapeutique |
| FR2866886B1 (fr) * | 2004-02-26 | 2007-08-31 | Sanofi Synthelabo | Derives d'aryl-et d'heteroaryl-akylcarbamates, leur preparation et leur application en therapeutique |
| FR2866885B1 (fr) | 2004-02-26 | 2007-08-31 | Sanofi Synthelabo | Derives de piperidinylalkylcarbamates, leur prepation et leur application en therapeutique |
| GB2415372A (en) | 2004-06-23 | 2005-12-28 | Destiny Pharma Ltd | Non photodynamical or sonodynamical antimicrobial use of porphyrins and azaporphyrins containing at least one cationic-nitrogen-containing substituent |
| TW200633990A (en) | 2004-11-18 | 2006-10-01 | Takeda Pharmaceuticals Co | Amide compound |
| EP2937341B1 (en) | 2004-12-30 | 2017-07-05 | Janssen Pharmaceutica N.V. | 4-(benzyl)-piperazine-1-carboxylic acid phenylamide derivatives and related compounds as modulators of fatty acid amide hydrolase (faah) for the treatment of anxiety, pain and other conditions |
| FR2885364B1 (fr) * | 2005-05-03 | 2007-06-29 | Sanofi Aventis Sa | Derives d'alkyl-, alkenyl-et alkynylcarbamates, leur preparation et leur application en therapeutique |
| US7541359B2 (en) | 2005-06-30 | 2009-06-02 | Janssen Pharmaceutica N.V. | N-heteroarylpiperazinyl ureas as modulators of fatty acid amide hydrolase |
| WO2008030752A2 (en) * | 2006-09-07 | 2008-03-13 | N.V. Organon | Methods for determining effective doses of fatty acid amide hydrolase inhibitors in vivo |
| EP1903037A1 (de) * | 2006-09-07 | 2008-03-26 | Bayer Schering Pharma Aktiengesellschaft | 1-(Het)aryl-3-[hetaryl-piperidin-4-yl]-thioharnstoffe als Modulatoren des EP2-Rezeptors |
| WO2008042892A2 (en) * | 2006-10-02 | 2008-04-10 | N.V. Organon | Fatty acid amide hydrolase inhibitors for energy metabolism disorders |
| US20080119549A1 (en) * | 2006-11-20 | 2008-05-22 | N.V. Organon | Metabolically-stabilized inhibitors of fatty acid amide hydrolase |
| TWI434842B (zh) * | 2008-07-14 | 2014-04-21 | Astellas Pharma Inc | Azole compounds |
| FR2934265B1 (fr) * | 2008-07-23 | 2010-07-30 | Sanofi Aventis | Derives de carbamates d'alkylthiazoles, leur preparation et leur application en therapeutique |
| FR2938537B1 (fr) * | 2008-11-14 | 2012-10-26 | Sanofi Aventis | Derives de carbamates d'alkyl-heterocycles, leur preparation et leur application en therapeutique. |
| FR2941696B1 (fr) * | 2009-02-05 | 2011-04-15 | Sanofi Aventis | Derives d'azaspiranyl-alkylcarbamates d'heterocycles a 5 chainons, leur preparation et leur application en therapeutique |
| EP2421848A1 (en) * | 2009-04-22 | 2012-02-29 | Janssen Pharmaceutica N.V. | Azetidinyl diamides as monoacylglycerol lipase inhibitors |
| FR2945531A1 (fr) * | 2009-05-12 | 2010-11-19 | Sanofi Aventis | Derives de 7-aza-spiro°3,5!nonane-7-carboxylates, leur preparation et leur application en therapeutique |
| US20120028931A1 (en) * | 2009-09-14 | 2012-02-02 | Recordati Ireland Limited | Heterocyclic m-glu5 antagonists |
| WO2011085216A2 (en) | 2010-01-08 | 2011-07-14 | Ironwood Pharmaceuticals, Inc. | Use of faah inhibitors for treating parkinson's disease and restless legs syndrome |
| US20130224151A1 (en) | 2010-03-31 | 2013-08-29 | United States Of America | Use of FAAH Inhibitors for Treating Abdominal, Visceral and Pelvic Pain |
| UA108233C2 (uk) | 2010-05-03 | 2015-04-10 | Модулятори активності гідролази амідів жирних кислот | |
| GB201017345D0 (en) | 2010-10-14 | 2010-11-24 | Proximagen Ltd | Receptor antagonists |
| MX350788B (es) * | 2012-01-06 | 2017-09-13 | Abide Therapeutics Inc | Compuestos de carbamato y preparación y uso de los mismos. |
| DE102012018115A1 (de) | 2012-09-13 | 2014-03-13 | Matthias Lehr | Aryl-N-(arylalkyl)carbamate als Hemmstoffe der Fatty Acid Amide Hydrolase |
| EP3022179B1 (en) | 2013-07-18 | 2017-11-15 | Fondazione Istituto Italiano Di Tecnologia | Phenyl carbamates and their use as inhibitors of the fatty acid amide hydrolase (faah) enzyme and modulators of the d3 dopamine receptor (d3dr) |
| DE102013016573A1 (de) | 2013-10-04 | 2015-04-09 | Matthias Lehr | 1-Tetrazolylpropan-2-one als Inhibitoren von cytosolischer Phospholipase A2 und Fatty Acid Amide Hydrolase, insbesondere geeignet zur topischen Anwendung |
| JP6927882B2 (ja) | 2015-04-02 | 2021-09-01 | プロキシマジェン，リミティド ライアビリティ カンパニー | 癌の新治療法 |
| JP2023550153A (ja) * | 2020-11-23 | 2023-11-30 | エフ． ホフマン－ラ ロシュ アーゲー | Ｂ型肝炎ウイルス感染症の処置および予防のためのｎ－［（１，３－ベンゾオキサゾル－２－イル）－複素環］アミド誘導体 |
Family Cites Families (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE3235565A1 (de) * | 1982-09-25 | 1984-03-29 | Boehringer Ingelheim KG, 6507 Ingelheim | Piperidinderivate, ihre herstellung und verwendung |
| FR2761266B1 (fr) * | 1997-03-28 | 1999-07-02 | Sanofi Sa | Composition pharmaceutique formee par granulation humide pour l'administration orale d'un derive du n-piperidino-3- pyrazolecarboxamide, de ses sels et de leurs solvates |
| FR2783246B1 (fr) * | 1998-09-11 | 2000-11-17 | Aventis Pharma Sa | Derives d'azetidine, leur preparation et les medicaments les contenant |
| FR2805818B1 (fr) * | 2000-03-03 | 2002-04-26 | Aventis Pharma Sa | Derives d'azetidine, leur preparation et les compositions pharmaceutiques les contenant |
| FR2816938B1 (fr) | 2000-11-22 | 2003-01-03 | Sanofi Synthelabo | Derives de 3-aroylindole, leur procede de preparation et les compositions pharmaceutiques en contenant |
| FR2843964B1 (fr) * | 2002-08-29 | 2004-10-01 | Sanofi Synthelabo | Derives de dioxane-2-alkylcarbamates, leur preparation et leur application en therapeutique |
-
2003
- 2003-05-07 FR FR0305540A patent/FR2854633B1/fr not_active Expired - Fee Related
-
2004
- 2004-05-06 BR BRPI0410123-5A patent/BRPI0410123A/pt not_active IP Right Cessation
- 2004-05-06 WO PCT/FR2004/001102 patent/WO2004099176A1/fr not_active Ceased
- 2004-05-06 CN CN2004800183223A patent/CN1812980B/zh not_active Expired - Fee Related
- 2004-05-06 AU AU2004236006A patent/AU2004236006B2/en not_active Ceased
- 2004-05-06 AR ARP040101538A patent/AR044178A1/es unknown
- 2004-05-06 EA EA200501477A patent/EA009468B1/ru not_active IP Right Cessation
- 2004-05-06 CN CN200910247187A patent/CN101712660A/zh active Pending
- 2004-05-06 MX MXPA05011941A patent/MXPA05011941A/es active IP Right Grant
- 2004-05-06 TW TW093112818A patent/TWI337607B/zh not_active IP Right Cessation
- 2004-05-06 NZ NZ542941A patent/NZ542941A/en not_active IP Right Cessation
- 2004-05-06 RS YUP-2005/0805A patent/RS20050805A/sr unknown
- 2004-05-06 JP JP2006505833A patent/JP4669836B2/ja not_active Expired - Fee Related
- 2004-05-06 ZA ZA200508158A patent/ZA200508158B/en unknown
- 2004-05-06 CA CA002521700A patent/CA2521700A1/en not_active Abandoned
- 2004-05-06 KR KR1020057021049A patent/KR20060009900A/ko not_active Abandoned
- 2004-05-06 EP EP04742661A patent/EP1633735B1/fr not_active Expired - Lifetime
- 2004-05-06 ME MEP-223/08A patent/MEP22308A/xx unknown
- 2004-05-06 AT AT04742661T patent/ATE535518T1/de active
- 2004-06-05 UA UAA200511617A patent/UA81808C2/uk unknown
-
2005
- 2005-10-06 TN TNP2005000253A patent/TNSN05253A1/en unknown
- 2005-10-13 IS IS8070A patent/IS8070A/is unknown
- 2005-10-28 US US11/262,211 patent/US7214798B2/en not_active Expired - Fee Related
- 2005-10-28 CO CO05110295A patent/CO5640105A2/es not_active Application Discontinuation
- 2005-10-31 IL IL171694A patent/IL171694A/en not_active IP Right Cessation
- 2005-11-02 MA MA28577A patent/MA27791A1/fr unknown
- 2005-11-04 NO NO20055204A patent/NO20055204L/no not_active Application Discontinuation
-
2007
- 2007-02-02 US US11/670,690 patent/US8034818B2/en not_active Expired - Fee Related
-
2010
- 2010-11-26 JP JP2010264051A patent/JP2011063620A/ja not_active Withdrawn
-
2011
- 2011-09-09 US US13/229,106 patent/US20120004207A1/en not_active Abandoned
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2006525293A5 (enExample) | ||
| ZA200508158B (en) | Derivatives of piperidinyl- and piperazinyl-alkyl carbamates, preparation methods thereof and application of same in therapeutics | |
| JP2005511532A5 (enExample) | ||
| JP2005530722A5 (enExample) | ||
| CA2690226A1 (en) | Novel malonic acid sulfonamide derivative and pharmaceutical use thereof | |
| JP2005509622A5 (enExample) | ||
| EA200500304A1 (ru) | Производные 3-(сульфонамидоэтил)индола, предназначенные для использования в качестве миметиков глюкокортикоидов при лечении воспалительных, аллергических и пролиферативных заболеваний | |
| JP2006524225A5 (enExample) | ||
| NO20045002L (no) | (1-4-piperidinyl) benzimidazolderivater som kan anvendes som histamin H3-antagonister | |
| JP2006524222A5 (enExample) | ||
| KR101360556B9 (ko) | 글리코피롤레이트 및 베타2 아드레날린 수용체아고니스트의 조합물 | |
| MX2009000649A (es) | Derivados de n-(amino-heteroaril)-1h-indol-2-carboxamidas, su preparacion y aplicacion en terapeutica. | |
| JP2010501478A5 (enExample) | ||
| WO2004089892A3 (en) | Diarylmethyl and related compounds having beta2 andrenergic receptor agonist and muscarinic receptor antagonist activity | |
| IL238479A0 (en) | c2 th5 receptor modulator preparations and methods of use | |
| SG166019A1 (en) | Quinoline derivatives and use thereof as mycobacterial inhibitors | |
| WO2008093024A3 (fr) | Derives de n-(amino-heteroaryl)-1h-pyrrolopyridine-2-carboxamides, leur préparation et leur application en therapeutique | |
| JP2017533968A5 (enExample) | ||
| WO2003024928A3 (en) | Novel aminoazetidine, -pyrrolidine and -piperidine derivatives | |
| RU2007130144A (ru) | Гетероциклические соединения в качестве антагонистов cccr2b | |
| JP2007520440A5 (enExample) | ||
| WO2007054770A3 (en) | Pyrazole derivatives and their medical use | |
| EP1398029A8 (en) | NR3B1 nuclear receptor binding 3-substituted pyrazole derivatives | |
| WO2007056219A3 (en) | [4-(6-halo-7-substituted-2,4-dioxo-1,4-dihydro-2h-quinazolin-3-yl)-phenyl]-5-chloro-thiophen-2-yl-sulfonylureas and forms and methods related thereto | |
| ATE318266T1 (de) | 3-substituierte chinolin-4- carbonsäureamidderivate als nk-3- und nk-2- rezeptorantagonisten |